title: Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
abstract: OBJECTIVE
  Attempts to increase survival in stage III ovarian cancer patients with minimal residual disease at second-look laparotomy have included consolidation radiotherapy. We present long-term survival of 106 consecutive patients treated between 1983 and 1993 in 4 French institutions for stage III ovarian adenocarcinoma with first-look debulking, cisplatin-based chemotherapy, second-look surgery with a residual disease <1 cm and consolidation radiotherapy.
  
  
  METHODS
  Median age was 52 years. Residual disease after first look surgery was <1 cm for 40.5% of patients. Median number of chemotherapy cycles was 6 (range 4-12). Residual disease <1 cm at second-look laparotomy was observed in 79% of the patients, with 33% of patients in complete histologic remission. Residual disease <1 cm was obtained in all patients after tumor excision during second-look surgery. Radiation was performed using a linear accelerator with a whole abdomen dose of 22.5 Gy, an additional 22 Gy pelvic boost for 71 patients, and an additional 12 Gy lombo-aortic boost for 33 patients.
  
  
  RESULTS
  Median follow-up was 14 years. Radiation was stopped for acute toxicity in 11 patients. Long-term toxicities included radiation enteritis in 21 patients with 9 patients requiring surgery for bowel obstruction. Four deaths were related to enteritis complications. Overall survival at 5 and 10 years was respectively 53% and 36%.
  
  
  CONCLUSIONS
  This sequential treatment with final consolidation abdominopelvic radiotherapy is an effective treatment for a selected group of stage III ovarian cancer patients with a high intestinal toxicity incidence.
authors.affiliation: CLCC Léon Bérard, Lyon, France. tpetit@strasbourg.fnclcc.fr
authors.forename: Thierry
authors.initials: T
authors.lastname: Petit
authors.forename: Michel
authors.initials: M
authors.lastname: Velten
authors.forename: Anne
authors.initials: A
authors.lastname: d'Hombres
authors.forename: Christian
authors.initials: C
authors.lastname: Marchal
authors.forename: Xavier
authors.initials: X
authors.lastname: Montbarbon
authors.forename: Françoise
authors.initials: F
authors.lastname: Mornex
authors.forename: Philippe
authors.initials: P
authors.lastname: Quetin
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Gérard
authors.forename: Pascale
authors.initials: P
authors.lastname: Romestaing
authors.forename: Christian
authors.initials: C
authors.lastname: Carrie
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007813:Laparotomy; D008875:Middle Aged; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D016609:Neoplasms, Second Primary / Q000209:etiology; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D011878:Radiotherapy / Q000009:adverse effects; D012189:Retrospective Studies; D024162:Second-Look Surgery; D016896:Treatment Outcome
chemical_list: D002945:Cisplatin